STAT+: 3 issues to watch in pharma in 2024

As another year comes to an end and the world seems to hit the proverbial pause button, the temptation to look ahead is too great to ignore. After all, this is what journalists like to do as the calendar turns another page. So once again, we will take a whack at identifying some of the most noteworthy developments to watch.

However, if these seem familiar, there is good reason. The fundamental issues and intriguing stories that characterized the year gone by will to continue to loom. So here goes….

Obesity

By far, weight loss treatments will remain the big story. And you know why: Demand is intense — so intense that, by 2030, the market for these medicines is forecast to hit $41 billion, according to analysts at TD Cowen. Their increasingly ubiquitous use is having a huge impact not only on patients and the companies that manufacturer these drugs — Novo Nordisk and Eli Lilly — but also investors, doctors, employers, insurers, regulators, and businesses in a variety of industries.

Continue to STAT+ to read the full story…